EX-99.1
3
c05145exv99w1.htm
PRESS RELEASE
exv99w1
DATE: May 9, 2006
FOR IMMEDIATE RELEASE
AMERICAN MEDICAL SYSTEMS ACQUIRES SOLARANT MEDICAL IN TARGETING OFFICE-BASED STRESS URINARY
INCONTINENCE SOLUTIONS
Development Efforts will Focus on Radiofrequency Technology as an Incisionless Incontinence
Therapy Option
MINNEAPOLIS, May 9, 2006 - American Medical Systems Holdings, Inc. (NASDAQ: AMMD) today
reported its acquisition of Solarant Medical, Inc., a privately funded company focused on the
development of minimally invasive therapies for women who suffer from stress urinary incontinence.
The purchase price is comprised of an initial payment and the potential for future payments linked
to certain key milestones including FDA approval of the therapy and the establishment of
reimbursement codes applicable to both the hospital and office settings. The former Solarant
shareholders would also receive an earnout based on revenues achieved during the first three years
in the event of product commercialization. In addition to these acquisition payments, AMS
previously funded $1.0 million of Solarant's development efforts. Specific details of this
acquisition will be filed with the SEC on Form 8-K.
Martin J. Emerson, President and Chief Executive Officer of American Medical Systems, commented,
"Office-based incontinence therapy will be the means by which physicians will ultimately reach a
significantly greater number of the 80 million women around the world suffering from stress
incontinence. We at AMS are eager to actively advance the development activities to this end based
upon the solid foundation of the Solarant intellectual property portfolio and product concepts".
About American Medical Systems
American Medical Systems, headquartered in Minnetonka, Minnesota is a diversified supplier of
medical devices and procedures to cure erectile dysfunction, benign prostatic hyperplasia,
incontinence, menorrhagia, prolapse and other pelvic disorders in men and women. These disorders
can significantly diminish one's quality of life and profoundly affect social relationships. In
recent years, the number of people seeking treatment has increased markedly as a result of longer
lives, higher quality-of-life expectations and greater awareness of new treatment alternatives.
American Medical Systems' products reduce or eliminate the incapacitating effects of these
diseases, often through minimally invasive therapies. The Company's products were used to provide
approximately 170,000 patient cures in 56 countries during 2005.
Forward-Looking Statements
Statements about the Company's market opportunities, future products, sales and financial results
are forward-looking statements subject to risks and uncertainties such as the timing and success of
new product introductions; physician acceptance, endorsement, and use of the Company's products;
regulatory matters; competitor activities; changes in and adoption of reimbursement rates;
potential product recalls and other risks and uncertainties described in the Company's Annual
Report on Form 10-K for the year ended December 31, 2005 and its other SEC filings. Actual results
may differ materially from anticipated results.
More information about the Company and its products can be found at its website
www.AmericanMedicalSystems.com
and in the Company's Annual Report on Form 10-K for 2005 and its
other SEC filings.
Contact:
Carmen Diersen
Executive Vice President and Chief Financial Officer
952-930-6495
Carmen.Diersen@AmericanMedicalSystems.com
Marty Emerson
President and Chief Executive Officer
952-930-6334
Marty.Emerson@AmericanMedicalSystems.com

EX - 99 . 1 3 c05145exv99w1 . htm PRESS RELEASE exv99w1 DATE : May 9 , 2006 FOR IMMEDIATE RELEASE AMERICAN MEDICAL SYSTEMS ACQUIRES SOLARANT MEDICAL IN TARGETING OFFICE - BASED STRESS URINARY INCONTINENCE SOLUTIONS Development Efforts will Focus on Radiofrequency Technology as an Incisionless Incontinence Therapy Option MINNEAPOLIS , May 9 , 2006 - American Medical Systems Holdings , Inc . ( NASDAQ : AMMD ) today reported its acquisition of Solarant Medical , Inc . , a privately funded company focused on the development of minimally invasive therapies for women who suffer from stress urinary incontinence . The purchase price is comprised of an initial payment and the potential for future payments linked to certain key milestones including FDA approval of the therapy and the establishment of reimbursement codes applicable to both the hospital and office settings . The former Solarant shareholders would also receive an earnout based on revenues achieved during the first three years in the event of product commercialization . In addition to these acquisition payments , AMS previously funded $ 1.0 million of Solarant 's development efforts . Specific details of this acquisition will be filed with the SEC on Form 8 - K . Martin J . Emerson , President and Chief Executive Officer of American Medical Systems , commented , " Office - based incontinence therapy will be the means by which physicians will ultimately reach a significantly greater number of the 80 million women around the world suffering from stress incontinence . We at AMS are eager to actively advance the development activities to this end based upon the solid foundation of the Solarant intellectual property portfolio and product concepts " . About American Medical Systems American Medical Systems , headquartered in Minnetonka , Minnesota is a diversified supplier of medical devices and procedures to cure erectile dysfunction , benign prostatic hyperplasia , incontinence , menorrhagia , prolapse and other pelvic disorders in men and women . These disorders can significantly diminish one 's quality of life and profoundly affect social relationships . In recent years , the number of people seeking treatment has increased markedly as a result of longer lives , higher quality - of - life expectations and greater awareness of new treatment alternatives . American Medical Systems ' products reduce or eliminate the incapacitating effects of these diseases , often through minimally invasive therapies . The Company 's products were used to provide approximately 170,000 patient cures in 56 countries during 2005 . Forward - Looking Statements Statements about the Company 's market opportunities , future products , sales and financial results are forward - looking statements subject to risks and uncertainties such as the timing and success of new product introductions ; physician acceptance , endorsement , and use of the Company 's products ; regulatory matters ; competitor activities ; changes in and adoption of reimbursement rates ; potential product recalls and other risks and uncertainties described in the Company ' s Annual Report on Form 10 - K for the year ended December 31 , 2005 and its other SEC filings . Actual results may differ materially from anticipated results . More information about the Company and its products can be found at its website www.AmericanMedicalSystems.com and in the Company 's Annual Report on Form 10 - K for 2005 and its other SEC filings . Contact : Carmen Diersen Executive Vice President and Chief Financial Officer 952 - 930 - 6495 Carmen.Diersen@AmericanMedicalSystems.com Marty Emerson President and Chief Executive Officer 952 - 930 - 6334 Marty.Emerson@AmericanMedicalSystems.com
O O O O O O O O O O O O O O O O O O O O O B-Parties.BUYING_COMPANY I-Parties.BUYING_COMPANY I-Parties.BUYING_COMPANY O B-Parties.ACQUIRED_COMPANY I-Parties.ACQUIRED_COMPANY O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B-Parties.BUYING_COMPANY I-Parties.BUYING_COMPANY I-Parties.BUYING_COMPANY I-Parties.BUYING_COMPANY I-Parties.BUYING_COMPANY I-Parties.BUYING_COMPANY I-Parties.BUYING_COMPANY O O O O O O O O O O B-Parties.ACQUIRED_COMPANY I-Parties.ACQUIRED_COMPANY I-Parties.ACQUIRED_COMPANY I-Parties.ACQUIRED_COMPANY I-Parties.ACQUIRED_COMPANY O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O